{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:59:24Z","timestamp":1776157164849,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1007\/s11894-003-0004-z","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T16:47:19Z","timestamp":1179593239000},"page":"9-17","source":"Crossref","is-referenced-by-count":20,"title":["The management of primary sclerosing cholangitis"],"prefix":"10.1007","volume":"5","author":[{"given":"Roger W.","family":"Chapman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gut.21.10.870","volume":"21","author":"RW Chapman","year":"1980","unstructured":"Chapman RW, Arborgh BA, Rhodes JM, et al.: Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980, 21:870\u2013877.","journal-title":"Gut"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/gut.33.10.1370","volume":"33","author":"SK Lo","year":"1992","unstructured":"Lo SK, Fleming KA, Chapman RW: Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992, 33:1370\u20131375.","journal-title":"Gut"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0016-5085(95)90473-5","volume":"108","author":"R Chapman","year":"1995","unstructured":"Chapman R: Does HLA status influence prognosis in primary sclerosing cholangitis? Gastroenterology 1995, 108:937\u2013940.","journal-title":"Gastroenterology"},{"key":"4_CR4","first-page":"988","volume":"23","author":"E Martins","year":"1996","unstructured":"Martins E, Graham AK, Chapman RW, Fleming KA: Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology 1996, 23:988\u2013993.","journal-title":"Hepatology"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.35.1.84","volume":"35","author":"U Broome","year":"1994","unstructured":"Broome U, Glaumann H, Hellers G, et al.: Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994, 35:84\u201389.","journal-title":"Gut"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gut.33.10.1376","volume":"33","author":"CS Pokorny","year":"1992","unstructured":"Pokorny CS, McCaughan GW, Gallagher ND, Selby WS: Sclerosing cholangitis and biliary tract calculi: primary or secondary? Gut 1992, 33:1376\u20131380.","journal-title":"Gut"},{"key":"4_CR7","first-page":"1404","volume":"22","author":"U Broome","year":"1995","unstructured":"Broome U, Loberg R, Veress B, Eriksso LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404\u20131408.","journal-title":"Hepatology"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/gast.1996.v110.pm8566577","volume":"110","author":"TA Brentnall","year":"1996","unstructured":"Brentnall TA, Haggitt RC, Rabinovitch PS, et al.: Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996, 110:331\u2013338.","journal-title":"Gastroenterology"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/BF02050624","volume":"36","author":"R Bleday","year":"1993","unstructured":"Bleday R, Lee E, Jessurun J, et al.: Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993, 36:908\u2013912.","journal-title":"Dis Colon Rectum"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/gut.38.2.234","volume":"38","author":"C Penna","year":"1996","unstructured":"Penna C, Dozois R, Tremaine W, et al.: Pouchitis after pouchanal anastomosierative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996, 38:234\u2013239.","journal-title":"Gut"},{"key":"4_CR11","first-page":"154A","volume":"20","author":"DF Mirza","year":"1994","unstructured":"Mirza DF, Davies M, Olliff S, et al.: Preoperative diagnosis of cholangiocarcinoma in primary sclerosing cholangitis in potential liver tranplantation candidates [abstract]. Hepatology 1994, 20:154A.","journal-title":"Hepatology"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0016-5107(94)70155-5","volume":"40","author":"AP Ferrunior","year":"1994","unstructured":"Ferrunior AP, Lichtenstein DR, Slivka A, et al.: Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994, 40:140\u2013148.","journal-title":"Gastrointest Endosc"},{"key":"4_CR13","first-page":"722","volume":"90","author":"JG Lee","year":"1995","unstructured":"Lee JG, Leung JW, Baillie J, et al.: Benign, dyplasitic or malignant \u2014making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995, 90:722\u2013726.","journal-title":"Am J Gastroenterol"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0016-5085(95)90462-X","volume":"108","author":"JK Ramage","year":"1995","unstructured":"Ramage JK, Donaghy A, Farrant JM, et al.: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995, 108:865\u2013869.","journal-title":"Gastroenterology"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archsurg.1994.01420340071012","volume":"129","author":"JA Hepburgh","year":"1994","unstructured":"Hepburgh JA: Surgical biliary drainage in primary sclerosing cholangitis: the role of the Hepp-Couinaud approach. Arch Surg 1994, 129:1057\u20131062.","journal-title":"Arch Surg"},{"key":"4_CR16","first-page":"661","volume":"21","author":"JG Lee","year":"1995","unstructured":"Lee JG, Schutz SM, England RE, et al.: Endoscopic therapy of sclerosing cholangitis. Hepatology 1995, 21:661\u2013667.","journal-title":"Hepatology"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/j.1572-0241.1999.01364.x","volume":"94","author":"CY Ponsioen","year":"1999","unstructured":"Ponsioen CY, Lam K, van Milligan de Wit AW, et al.: Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:2403\u20132407.","journal-title":"Am J Gastroenterol"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0016-5085(88)90180-1","volume":"95","author":"NF LaRusso","year":"1988","unstructured":"LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036\u20131042.","journal-title":"Gastroenterology"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004836-198109000-00010","volume":"3","author":"M Sivak Jr.","year":"1981","unstructured":"Sivak M Jr., Farmer RG, Lalli AF: Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease. J Clin Gastroenterol 1981, 3:261\u2013266.","journal-title":"J Clin Gastroenterol"},{"key":"4_CR20","first-page":"1037","volume":"86","author":"SL Burgert","year":"1984","unstructured":"Burgert SL, Brown BP, Kirkpatrick RB, et al.: Positive corticosteroid response in early primary sclerosing cholangitis [abstract]. Gastroenterology 1984, 86:1037.","journal-title":"Gastroenterology"},{"key":"4_CR21","first-page":"57","volume":"86","author":"KD Lindor","year":"1991","unstructured":"Lindor KD, Wiesner RH, Colwell LJ, et al.: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 86:57\u201361.","journal-title":"Am J Gastroenterol"},{"key":"4_CR22","first-page":"1462","volume":"23","author":"MK Porayko","year":"1991","unstructured":"Porayko MK, Wiesner RH, Hay JE, et al.: Bone disease in liver transplant recipients: incidence, timing and risk factors. Transplant Proc 1991, 23:1462\u20131465.","journal-title":"Transplant Proc"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/BF01296045","volume":"31","author":"R Grijm","year":"1986","unstructured":"Grijm R, Huibregtse K, Bartelsman J, et al.: Therapeutic investigations in primary sclerosing cholangitis. Dig Dis Sci 1986, 31:792\u2013798.","journal-title":"Dig Dis Sci"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-1746.1990.tb01818.x","volume":"5","author":"GP Jeffrey","year":"1990","unstructured":"Jeffrey GP, Reed WD, Laurence BH, et al.: Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J Gastroenterol Hepatol 1990, 5:135\u2013140.","journal-title":"J Gastroenterol Hepatol"},{"key":"4_CR25","first-page":"1182a","volume":"31","author":"PI Craig","year":"1990","unstructured":"Craig PI, Williams SJ, Hatfield ARW, et al.: Endoscopic management of primary sclerosing cholangitis [abstract]. Gut 1990, 31:1182a.","journal-title":"Gut"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0168-8278(86)80155-6","volume":"3","author":"MC Allison","year":"1986","unstructured":"Allison MC, Burroughs AK, Noone P, Summerfield JA: Biliary lavage with corticosteroids in primary sclerosing cholangitis: a clinical, cholangiographic and bacteriological study. J Hepatol 1986, 3:118\u2013122.","journal-title":"J Hepatol"},{"key":"4_CR27","first-page":"477A","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Jorgensen A, Lindor KD: Budesonide in the treatment of primary sclerosing cholangitis: a pilot study [abstract]. Hepatology 1999, 30:477A.","journal-title":"Hepatology"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0002-9270(00)01059-5","volume":"95","author":"HJF Hoogstraten van","year":"2000","unstructured":"van Hoogstraten HJF, Vieggar FP, Boland GI, et al.: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol 2000, 95:2015\u20132022.","journal-title":"Am J Gastroenterol"},{"key":"4_CR29","first-page":"546","volume":"86","author":"TA Knox","year":"1991","unstructured":"Knox TA, Kaplan MM: Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991, 86:546\u2013552.","journal-title":"Am J Gastroenterol"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0016-5085(94)90610-6","volume":"106","author":"TA Knox","year":"1994","unstructured":"Knox TA, Kaplan MM: A double-blind controlled trial of oralpulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494\u2013499.","journal-title":"Gastroenterology"},{"key":"4_CR31","first-page":"511","volume":"91","author":"KD Lindor","year":"1996","unstructured":"Lindor KD, Jorgensen RA, Anderson ML, et al.: Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996, 91:511\u2013515.","journal-title":"Am J Gastroenterol"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(71)91261-X","volume":"1","author":"SL Javett","year":"1971","unstructured":"Javett SL: Azathioprine in primary sclerosing cholangitis. Lancet 1971, 1:810\u2013811.","journal-title":"Lancet"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0140-6736(71)80107-1","volume":"2","author":"A Wagner","year":"1971","unstructured":"Wagner A: Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971, 2:663\u2013664.","journal-title":"Lancet"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"63A","DOI":"10.1002\/hep.1840140424","volume":"14","author":"RH Wiesner","year":"1991","unstructured":"Wiesner RH, Steiner B, LaRusso NF, et al.: A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis [abstract]. Hepatology 1991, 14:63A.","journal-title":"Hepatology"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/gut.34.2.242","volume":"34","author":"WJ Sandborn","year":"1993","unstructured":"Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993, 34:242\u2013246.","journal-title":"Gut"},{"key":"4_CR36","first-page":"449","volume":"41","author":"K Kyokane","year":"1994","unstructured":"Kyokane K, Ichihara T, Horisawa M, et al.: Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994, 41:449\u2013452.","journal-title":"Hepatogastroenterology"},{"key":"4_CR37","first-page":"455","volume":"90","author":"DH Van-Thiel","year":"1995","unstructured":"Van-Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455\u2013459.","journal-title":"Am J Gastroenterol"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-200012000-00005","volume":"31","author":"A Duchini","year":"2000","unstructured":"Duchini A, Younossi ZM, Saven A, et al.: An open-label pilot trial of cladibrine (2-cloolordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000, 31:271\u2013273.","journal-title":"J Clin Gastroenterol"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2000.02324.x","volume":"95","author":"AE Bharucha","year":"2000","unstructured":"Bharucha AE, Jorgensen R, Lichtman SN, et al.: A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2338\u20132342.","journal-title":"Am J Gastroenterol"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","volume":"108","author":"R Olsson","year":"1995","unstructured":"Olsson R, Broome U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199\u20131203.","journal-title":"Gastroenterology"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0016-5085(94)94899-2","volume":"106","author":"RP Jazrawi","year":"1994","unstructured":"Jazrawi RP, de-Caestecker JS, Goggin PM, et al.: Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994, 106:134\u2013142.","journal-title":"Gastroenterology"},{"key":"4_CR42","first-page":"92A","volume":"16","author":"SK Lo","year":"1992","unstructured":"Lo SK, Hermann R, Chapman RW, et al.: Ursodeoxycholic acid in primary sclerosing cholangitis: a double blind controlled trial [abstract]. Hepatology 1992, 16:92A.","journal-title":"Hepatology"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00042737-199902000-00013","volume":"11","author":"AW Milligen de Wit van","year":"1999","unstructured":"van Milligen de Wit AW, Kuiper H, Camoglio L, et al.: Does ursodeoxycholic acid mediate immunomodulatory and antiinflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastroenterol Hepatol 1999, 11:129\u2013136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/hep.1840140516","volume":"14","author":"CB O\u2019Brien","year":"1991","unstructured":"O\u2019Brien CB, Senior JR, Arora-Mirchandani R, et al.: Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991, 14:838\u2013847.","journal-title":"Hepatology"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","volume":"16","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Kruis W, et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707\u2013714.","journal-title":"Hepatology"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","volume":"20","author":"A Stiehl","year":"1994","unstructured":"Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57\u201364.","journal-title":"J Hepatol"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"KD Lindor","year":"1997","unstructured":"Lindor KD, for the Mayo PSC\/UDCA Study Group: Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997, 336:691\u2013695. A large controlled trial showing that conventional doses of UDCA (10-15 mg\/kg) were of no benefit.","journal-title":"N Engl J Med"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jcp.48.10.933","volume":"48","author":"R Olsson","year":"1995","unstructured":"Olsson R, Hagerstrand I, Broome U, et al.: Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995, 48:933\u2013935.","journal-title":"J Clin Pathol"},{"key":"4_CR49","first-page":"283","volume":"23","author":"A Stiehl","year":"1995","unstructured":"Stiehl A, Rudolph G, Sauer P, Theilmann L: Biliary secretion of bile acids and lipids in primary sclerosing cholangitis: influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995, 23:283\u2013289.","journal-title":"J Hepatol"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF01211187","volume":"31","author":"F Hirano","year":"1996","unstructured":"Hirano F, Tanaka H, Makino Y, et al.: Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression. J Gastoenterol 1996, 31:55\u201360.","journal-title":"J Gastoenterol"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastoenterology 2001, 121:900\u2013907. Twenty-six patints with PSC were randomly assigned to either highdose UDCA (20-25 mg \/kg\/d) or placebo for 2 years. Significant improvement was seen in liver tests, histology, and cholangiography in the UDCA group.","journal-title":"Gastoenterology"},{"key":"4_CR52","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","volume":"96","author":"DM Harnois","year":"2001","unstructured":"Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558\u20131566. In this pilot study, 30 patients with PSC were treated with high-dose UDCA (25 to 30 mg\/kg\/d) for 1 year. There was a marked improvement in liver tests and significant improvement in Mayo Risk Score compared with both palacebo and low-dose UDCA.","journal-title":"Am J Gastroenterol"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03401914","volume":"4","author":"CM Rodrigues","year":"1998","unstructured":"Rodrigues CM, Fan G, Wong PY, et al.: Ursodeoxycholic acid may inhibit deoxycholic acid-induced aopotosis by modulating mitochondrial transmembrane potential and reactive species production. Mol Med 1998, 4:165\u2013178.","journal-title":"Mol Med"},{"key":"4_CR54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/01635589809514689","volume":"31","author":"JD Martinez","year":"1998","unstructured":"Martinez JD, Stratagoules ED, La Rue JM, et al.: Different bile acids exhibit distinct biological effects. Nutr Cancer 1998, 31:111\u2013118. An in vitro study showing that UDCA inhibits apoptosis in tumor cell lines induced by deoxycholic acid.","journal-title":"Nutr Cancer"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","volume":"134","author":"BY Tung","year":"2001","unstructured":"Tung BY, Edmond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89\u201395. In this study 59 patients with both PSC and UC received surveillance colonoscopy every 3 years. UDCA was significantly less common in patients with dysplasia than in those without dysplasia.","journal-title":"Ann Intern Med"},{"key":"4_CR56","first-page":"2276","volume":"121","author":"JM Wolf","year":"2001","unstructured":"Wolf JM, Rybicki L, Lashner BA: Ursodeoxycholic acid is not chemoprotective for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis [abstract]. Gastroenterology 2001, 121:2276.","journal-title":"Gastroenterology"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1023\/A:1026673811278","volume":"44","author":"P Angulo","year":"1999","unstructured":"Angulo P, Bharucha AE, Jorgensen RA, et al.: Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999, 44:602\u2013607.","journal-title":"Dig Dis Sci"},{"key":"4_CR58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-131-12-199912210-00006","volume":"131","author":"C Schramm","year":"1999","unstructured":"Schramm C, Schirmacher P, Helmreich-Becker I, et al.: Combined therapy with azathioprine prednisolone and ursodiol in patients with primary sclerosing cholangitis: a case series. Ann Intern Med 1999, 131:943\u2013946. A pilot study showing that combined immunosuppressive therapy may have added benefit in treatment of PSC.","journal-title":"Ann Intern Med"},{"key":"4_CR59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(97)80421-7","volume":"26","author":"A Stiehl","year":"1997","unstructured":"Stiehl A, Rudolph G, Sauer P, et al.: Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis: an 8-year prospective study. J Hepatol 1997, 26:56\u201361.","journal-title":"J Hepatol"},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-0676.2000.020002097.x","volume":"20","author":"PJ Gow","year":"2000","unstructured":"Gow PJ, Chapman RW: Liver transplantation for primary sclerosing cholangitis. Liver 2000, 20:97\u2013103.","journal-title":"Liver"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0039-6060(05)80078-9","volume":"117","author":"O Farges","year":"1995","unstructured":"Farges O, Malassagne B, Sebagh M, Bismuth H: Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995, 117:146\u2013155.","journal-title":"Surgery"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.510290427","volume":"29","author":"IW Graziadei","year":"1999","unstructured":"Graziadei IW, Wiesner RH, Batts KP, et al.: Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999, 29:1050\u20131056. An important study documenting the high rate of recurrence (30%) at 5 years of PSC in the graft.","journal-title":"Hepatology"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","volume":"29","author":"HJ Hoogstraten van","year":"1998","unstructured":"van Hoogstraten HJ, Wolfhagen FJ, Van de Meeberg PC, et al.: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single vrsus multiple doses. J Hepatol 1998, 29:417\u2013423.","journal-title":"J Hepatol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-003-0004-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-003-0004-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-003-0004-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:03:44Z","timestamp":1559419424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-003-0004-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11894-003-0004-z","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}